Biotechnology firm Novavax has acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, NVX‑CoV2373.
The acquisition covers a 150,000ft2 vaccine and biologics manufacturing facility and related assets in Bohumil, Czech Republic, as well as the existing employees along with all associated and necessary infrastructure.
Novavax estimates that the manufacturing facility will enable an annual capacity of more than one billion doses of antigen, from next year, for its Covid-19 vaccine candidate.
Praha Vaccines is a subsidiary of the Cyrus Poonawalla Group, the parent company of Serum Institute of India focused on manufacturing immuno-biologicals.